Skip to main content
SpringerLink
Log in
Book cover

NSAIDs and Aspirin pp 91–104Cite as

Safe Prescription of NSAIDs in Clinical Practice

  • Chapter
  • First Online:

  • 2097 Accesses

Abstract

NSAIDs are among the most frequently prescribed medications worldwide and are used in many medical conditions to alleviate pain and inflammation. Their use has continued despite long-known gastrointestinal adverse events and mucosal damage throughout the gastrointestinal tract. The damage is not limited to the upper gastrointestinal tract, and lower gastrointestinal adverse events are as common as those in the upper gastrointestinal tract. COX-2 inhibitors carry less gastrointestinal side effects than nonselective NSAIDs, but the cardiovascular profile is comparable to that of nonselective NSAIDs and may limit the use of both classes of drugs. Clinicians should be aware of potential adverse events and approaches to improve the safety profile including eradication of Helicobacter pylori (H. pylori) infection, coadministration of proton pump inhibitors (PPIs), using the lowest required dose and frequency of dosing, choosing an NSAID with a better safety profile, considering both gastrointestinal and cardiovascular risks, and individualizing the care of the patient. Education of the patient and ensuring adherence to prescribed medication are also key to optimizing the risk/benefit associated with the use of NSAIDs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Blackler RW, Gemici B, Manko A, Wallace JL. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol. 2014;19:11–6.

    Article  CAS  PubMed  Google Scholar 

  2. Bjarnason I, Williams P, So A, Zanelli G, Levi A, Gumpel J, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;24:1171–4.

    Article  Google Scholar 

  3. Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis. 2013;45:390–5.

    Article  CAS  PubMed  Google Scholar 

  4. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–22.

    Article  CAS  PubMed  Google Scholar 

  5. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633–41.

    Article  PubMed  Google Scholar 

  6. Zhao Y, Encinosa W. Hospitalizations for gastrointestinal bleeding in 1998 and 2006. Healthcare Cost and Utilization Project (HCUP) Statistical Brief #65 [report on the Internet]. Agency for Healthcare Research and Quality, Rockville, MD. [Last Accessed Nov 7, 2015.]. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb65.jsp

  7. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241–9.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip OA: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–81.

    Article  CAS  PubMed  Google Scholar 

  9. Sudano I, Flammer AJ, Périat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122(18):1789–96.

    Article  CAS  PubMed  Google Scholar 

  10. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol. 2007;34:543–55.

    CAS  PubMed  Google Scholar 

  11. Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001;111:521–7.

    Article  CAS  PubMed  Google Scholar 

  12. Murray MD, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci. 1990;299:222–9.

    Article  CAS  PubMed  Google Scholar 

  13. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des. 2000;6:1737–53.

    Article  CAS  PubMed  Google Scholar 

  14. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci. 2005;35:347–85.

    CAS  PubMed  Google Scholar 

  15. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–66.

    Article  CAS  PubMed  Google Scholar 

  18. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–9.

    Article  CAS  PubMed  Google Scholar 

  19. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–74.

    Article  CAS  PubMed  Google Scholar 

  20. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–41.

    Article  PubMed  Google Scholar 

  21. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003;98:1725–33.

    Article  CAS  PubMed  Google Scholar 

  22. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124:288–92.

    Article  CAS  PubMed  Google Scholar 

  23. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–8.

    Article  CAS  PubMed  Google Scholar 

  24. Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135:1517–25.

    Article  CAS  PubMed  Google Scholar 

  25. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211–22.

    Article  CAS  PubMed  Google Scholar 

  26. Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008;6:536–44.

    Article  CAS  PubMed  Google Scholar 

  27. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5:1040–5.

    Article  PubMed  Google Scholar 

  28. Yang M, Wang HT, Zhao M, Meng WB, Ou JQ, He JH, Zou B, Lei PG. Network meta-analysis comparing relatively selective COX-2 inhibitors versus Coxibs for the prevention of NSAID-induced gastrointestinal injury. Medicine (Baltimore). 2015;94(40), e1592.

    Article  CAS  Google Scholar 

  29. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009;41(6):423–37.

    Article  CAS  PubMed  Google Scholar 

  30. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490–6.

    Article  CAS  PubMed  Google Scholar 

  31. Fiorucci S, Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem. 2011;18:3494–505.

    Article  CAS  PubMed  Google Scholar 

  32. Wallace J. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med. 1996;19:346–51.

    CAS  PubMed  Google Scholar 

  33. Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C, STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64(3):449–56.

    Article  CAS  PubMed  Google Scholar 

  34. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19:1861–76.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012;7, e35196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hernandez-Diaz S, Garcia-Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.

    Article  CAS  PubMed  Google Scholar 

  37. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: confusion or confounding? Am J Med. 2006;119:719–27.

    Article  CAS  PubMed  Google Scholar 

  38. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367–70.

    Article  PubMed  Google Scholar 

  39. de Abajo FJ, Montero D, Garcia-Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006;98:304–10.

    Article  PubMed  Google Scholar 

  40. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: Benefits and risks of therapeutic strategies. Ann Med. 2006;38:415–28.

    Article  CAS  PubMed  Google Scholar 

  41. Lanas A, Ballina J, Sobreviela E, et al. Recent advances in the field of NSAID-associated side effects are not appropriately translated into clinical practice. Gastroenterology. 2007;132 Suppl 2:A86.

    Google Scholar 

  42. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.

    Article  CAS  PubMed  Google Scholar 

  43. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.

    Article  CAS  PubMed  Google Scholar 

  44. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–9.

    Article  CAS  PubMed  Google Scholar 

  45. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016–21.

    Article  CAS  PubMed  Google Scholar 

  46. de Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter. 2007;12:477–85.

    Article  PubMed  Google Scholar 

  47. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2003;17:799–805.

    Article  CAS  PubMed  Google Scholar 

  48. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8.

    Article  CAS  PubMed  Google Scholar 

  49. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967–73.

    Article  CAS  PubMed  Google Scholar 

  50. Labenz J, Blum AL, Bolten WW, Dragosics B, Rosch W, Stolte M, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646–64.

    Article  CAS  PubMed  Google Scholar 

  52. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, RH H, International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Coté GA, Rice JP, Bulsiewicz W, Norvell JP, Christensen K, Bobb A, Postelnick M, Howden CW. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. Am J Gastroenterol. 2008;103:1097–103.

    Article  PubMed  Google Scholar 

  54. Lanas A, Polo-Tomás M, Roncales P, Gonzalez MA, Zapardiel J. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol. 2012;107(5):707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin (Barc). 2000;114 Suppl 3:46–53.

    Google Scholar 

  56. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Nauclér E, Svedberg LE. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97(10):797–802.

    Google Scholar 

  57. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, et al. Primary gastro duodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12:135–40.

    Article  CAS  PubMed  Google Scholar 

  58. Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non- steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996;31:753–8.

    Article  CAS  PubMed  Google Scholar 

  59. Lin KJ, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;141:71–9.

    Article  CAS  PubMed  Google Scholar 

  60. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii–iv. 1–164.

    Article  CAS  PubMed  Google Scholar 

  61. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastro-duodenal ulcers. Cochrane Database Syst Rev. 2004;(4)CD002296.

    Google Scholar 

  62. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709–15.

    Article  CAS  PubMed  Google Scholar 

  63. Yoda Y, Amagase K, Kato S, et al. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol. 2010;61:287–94.

    CAS  PubMed  Google Scholar 

  64. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–44.

    Article  CAS  PubMed  Google Scholar 

  65. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.

    Article  CAS  PubMed  Google Scholar 

  66. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Bhatt DL, Cryer BL, Contant CF, Investigators COGENT, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.

    Article  CAS  PubMed  Google Scholar 

  68. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–26.

    Article  CAS  PubMed  Google Scholar 

  69. Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339–46.

    Article  PubMed  Google Scholar 

  70. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci. 1993;38:417–25.

    Article  CAS  PubMed  Google Scholar 

  71. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID- induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.

    Article  CAS  PubMed  Google Scholar 

  72. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo- controlled study of misoprostol vs. lansoprazole. Arch Intern Med. 2002;162:169–75.

    Article  CAS  PubMed  Google Scholar 

  73. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43:270–6.

    Article  CAS  PubMed  Google Scholar 

  74. Kim DH, Na HK, Oh TY, Kim WB, Surh YJ. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces cell cycle arrest in ras-transformed human mammary epithelial cells. Biochem Pharmacol. 2004;68:1081–7.

    Article  CAS  PubMed  Google Scholar 

  75. Lee KN, Lee OY, Choi MG, Choi SR, Lee DH, Lee YC, Kim TN, Choi SC, Rew JS, Seol SY. Prevention of NSAID-associated gastroduodenal injury in healthy volunteers-a randomized, double-blind, multicenter study comparing DA- 9601 with misoprostol. J Korean Med Sci. 2011;26:1074–80.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lee OY, Kang DH, Lee DH, Chung IK, Jang JY, Kim JI, Cho JW, Rew JS, Lee KM, Kim KO, Choi MG, Lee SW, Lee ST, Kim TO, Shin YW, Seol SY. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch Pharm Res. 2014;37(10):1308–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial b-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 2014;44:28–35.

    Article  CAS  PubMed  Google Scholar 

  78. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ, American College of Cardiology Foundation, American College of Gastroenterology, American Heart Association. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103(11):2890–907.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, McMaster University, 1280 Main Street West, Rm-3V3, Hamilton, ON, Canada, L8S 4K1

    Mohammad Yaghoobi M.D., M.S. (Epi.), A.F.S.

  2. Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada

    Richard H. Hunt F.R.C.P.Ed., F.R.C.P.C.

Authors
  1. Mohammad Yaghoobi M.D., M.S. (Epi.), A.F.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard H. Hunt F.R.C.P.Ed., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Yaghoobi M.D., M.S. (Epi.), A.F.S. .

Editor information

Editors and Affiliations

  1. IIS Aragón, CIBER Enfermedades Hepáicas y Digestivas (CIBERehd), Universidad de Zaragoza, Zaragoza, Spain

    Angel Lanas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Yaghoobi, M., Hunt, R.H. (2016). Safe Prescription of NSAIDs in Clinical Practice. In: Lanas, A. (eds) NSAIDs and Aspirin. Springer, Cham. https://doi.org/10.1007/978-3-319-33889-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33889-7_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33887-3

  • Online ISBN: 978-3-319-33889-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation